KRAS and colorectal carcinoma: Approximately eighty percent of CRC tumors can be distinguished by the accumulation of alterations in specific oncogenes (e.g., APC, KRAS, PIK3CA, SMAD4) and tumor suppressor genes, which thereby activate pathways that are critical for CRC tumorigenesis (Muller et al., 2016).